Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ

CONCLUSION: Our findings suggest that cost-effective and clinically optimal treatment strategies are RT alone for standard-risk DCIS and observation for good-risk DCIS, with personalization on the basis of patient age and preference for RT. Hormonal therapy is likely suboptimal for most patients with DCIS.PMID:34019456 | DOI:10.1200/JCO.21.00831
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research